These agents include FMS‐like tyrosine kinase 3 (FLT3) and Hedgehog pathway inhibitors, both of which disrupt discrete signalling pathways crucial for leukaemia cell growth, proliferation and survival [13]; isocitrate dehydrogenase (IDH) inhibitors, which block mutant IDH enzyme activity in leukaemia cells and prevent the production of R‐2‐hydroxyglutarate, a mediator of the cells’ oncogenic potential [14]; monoclonal antibodies against CD33 [5] and B‐cell lymphoma 2 (BCL‐2) inhibitors, which inhibit the antiapoptotic BCL‐2 protein that is overexpressed in malignant cells [4]. This evidence concerns the gene BCL2 and leukemia.